Skip to Content

UCB SA UCB

Morningstar Rating
€139.10 +2.25 (1.64%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Additional Indications for UCB's Bimzelx Could Drive Growth as Generics Weigh on Portfolio

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid pharma/chemical firm into a pure-play biopharmaceutical company by shedding its packaging, film, and chemical businesses. Acquisitions of Celltech (2004) and Schwarz Pharma (2006) strengthened the biopharmaceutical pipeline, bringing in late-stage assets that would eventually be approved as Cimzia (immunology), Vimpat (epilepsy), and Neupro (Parkinson's disease). These key products helped offset the impact of Zyrtec and Keppra's patent losses, and the company has continued to shape its expertise in immunology and central nervous system disorders.

Price vs Fair Value

UCB is trading within a range we consider fairly valued.
Price
€139.10
Fair Value
€47.00
Uncertainty
Medium
1-Star Price
€395.89
5-Star Price
€32.50
Economic Moat
Ghn
Capital Allocation
Cvrhdtbtl

Bulls Say, Bears Say

Bulls

The immunology market presents a massive market opportunity for Cimzia and newer drug Bimzelx.

Bears

The company has had a mixed record with regulatory delays and clinical failures, which could affect future revenue growth.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if UCB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
€136.85
Day Range
€135.50139.10
52-Week Range
€65.40139.10
Bid/Ask
€135.00 / €139.20
Market Cap
€26.40 Bil
Volume/Avg
1.3 Mil / 309,322

Key Statistics

Price/Earnings (Normalized)
29.91
Price/Sales
5.17
Dividend Yield (Trailing)
0.98%
Dividend Yield (Forward)
0.98%
Total Yield
1.13%

Company Profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
9,083

Competitors

Valuation

Metric
UCB
EXEL
JAZZ
Price/Earnings (Normalized)
29.9122.316.33
Price/Book Value
2.943.081.84
Price/Sales
5.173.801.95
Price/Cash Flow
29.6420.506.21
Price/Earnings
UCB
EXEL
JAZZ

Financial Strength

Metric
UCB
EXEL
JAZZ
Quick Ratio
0.843.231.62
Current Ratio
1.323.462.27
Interest Coverage
3.881.86
Quick Ratio
UCB
EXEL
JAZZ

Profitability

Metric
UCB
EXEL
JAZZ
Return on Assets (Normalized)
5.10%9.61%11.13%
Return on Equity (Normalized)
8.82%12.20%35.21%
Return on Invested Capital (Normalized)
7.41%8.59%16.02%
Return on Assets
UCB
EXEL
JAZZ
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
SsdjmgqlpdZcw$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
RzkxsfldsZxspfnj$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
TyslwbsqqYvfsgk$116.0 Bil
Moderna Inc
MRNA
ZdphbdllrNpkxm$51.1 Bil
argenx SE ADR
ARGX
JrkkjlpTxt$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
PcnrpncbHjlffzt$21.0 Bil
BioNTech SE ADR
BNTX
BykvqsnRbywz$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
KzkxyftfLhlpzww$15.9 Bil
United Therapeutics Corp
UTHR
SbzhxzhrCgvv$14.0 Bil
Incyte Corp
INCY
MjdnjzgzHrzvn$12.5 Bil

Sponsor Center